Please assess the completion status of the following clinical trial:

Trial Title: Development of Ivermectin for Alcohol Use Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 21 and 65;~* meet current DSM-V diagnostic criteria for an alcohol use disorder~Exclusion Criteria:~* current treatment for alcohol problems, a history of treatment in the 30 days before enrollment or current treatment seeking;~* a current (last 12 months) DSM-V diagnosis of dependence on any psychoactive substances other than alcohol and nicotine;~* a lifetime DSM-IV diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder;~* positive urine screen for narcotics, amphetamines, or sedative hypnotics;~* serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-R);~* pregnancy, nursing, or refusal to use reliable method of birth control (if female);~* a medical condition that may interfere with safe study participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes);~* AST, ALT, or GGT ≥ 3 times upper normal limit;~* currently on prescription medication that contraindicates use of IVN;~* any other circumstances that, in the opinion of the investigators, compromises participant safety.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ivermectin (Type: EXPERIMENTAL): Ivermectin 30 mg single dose
- Sugar pill (Type: PLACEBO_COMPARATOR): Matched placebo, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).